

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2022 ANNUAL REPORT AND THE 2023 INTERIM REPORT

Reference is made to (i) the annual report of Kintor Pharmaceutical Limited (the “**Company**”) for the year ended 31 December 2022 published on 28 April 2023 (the “**2022 Annual Report**”); and (ii) the interim report of the Company for the six months ended 30 June 2023 published on 27 September 2023 (the “**2023 Interim Report**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meaning as those defined in the 2022 Annual Report and 2023 Interim Report.

SUPPLEMENTAL INFORMATION ON THE 2022 ANNUAL REPORT

The Board would like to provide further information on the 2022 Annual Report regarding the detailed breakdown and description of the proceeds from the Global Offering and the Top-up Placing 2021 during the financial year ended 31 December 2022 as underlined below:

Use of Proceeds — Global Offering

| | Approximate % of total proceeds | Planned use of actual net proceeds <i>HKD (million)</i> | Utilised net proceeds during 2022 <i>HKD (million)</i> | Utilised net proceeds up to 31 December 2022 <i>HKD (million)</i> |
|--|---------------------------------------|--|---|--|
| Development and commercialisation of Prixelutamide | 42.0 | 721.3 | 260.8 | 721.3 |
| Development and commercialisation of KX-826 | 28.0 | 480.8 | 360.2 | 480.8 |
| Our ongoing and planned clinical trials for our other clinical-stage drug candidates | 14.0 | 240.4 | 115.5 | 240.4 |
| The R&D of pre-clinical stage drug candidates | 6.0 | 103.1 | – | 103.1 |
| Working capital and general corporate purposes | 10.0 | 171.7 | – | 171.7 |
| Total | 100.0 | 1,717.3 | 736.5 | 1,717.3 |

Use of Proceeds — 2021 Top-up Placing

| | Approximate % of total proceeds | Planned use of actual net proceeds <i>HKD (million)</i> | Utilised net proceeds during 2022 <i>HKD (million)</i> | Utilised net proceeds up to 31 December 2022 <i>HKD (million)</i> |
|---|---------------------------------------|--|---|--|
| Phase III multi-regional clinical trials (MRCT) of Prixelutamide in the U.S., China and a few other countries | 60.0 | 696.0 | 306.9 | 696.0 |
| Procurement of study material and active pharmaceutical ingredient (API) in preparation for the commercialisation of Prixelutamide | 33.0 | 382.8 | 69.9 | 382.8 |
| Working capital for general corporate purpose | 7.0 | 81.2 | – | 81.2 |
| Total | <u>100.0</u> | <u>1,160.0</u> | <u>376.8</u> | <u>1,160.0</u> |

SUPPLEMENTAL INFORMATION ON THE 2023 INTERIM REPORT

The Board would also like to provide further information on the 2023 Interim Report regarding the detailed breakdown and description of the proceeds from the Top-up Placing 2022-I and Top-up Placing 2022-II during the six months ended 30 June 2023 as underlined below:

Use of Proceeds — Top-up Placing 2022-I

| | Approximate % of total proceeds | Planned use of actual net proceeds <i>HKD (million)</i> | Utilised net proceeds during the six months ended 30 June 2023 <i>HKD (million)</i> | Utilised net proceeds up to 30 June 2023 <i>HKD (million)</i> |
|--|---------------------------------------|--|---|---|
| Clinical development and preparation for the commercialisation of Prixelutamide | 75.0 | 204.8 | — | 204.8 |
| Clinical development of KX-826 | 25.0 | 68.3 | 32.3 | 68.3 |
| Total | 100.0 | 273.0 | 32.3 | 273.0 |

Use of Proceeds — Top-up Placing 2022-II

| | Revised allocation of net proceeds % <i>HKD (million)</i> | Utilised net proceeds during the six months ended 30 June 2023 <i>HKD (million)</i> | Utilised net proceeds up to 30 June 2023 <i>HKD (million)</i> | Unutilised net proceeds as at 30 June 2023 <i>HKD (million)</i> | Expected timeline for utilizing the remaining balance of net proceeds from the top-up placing | |
|---|--|---|---|---|--|--|
| Clinical development of KX-826 for the treatment of AGA and acne vulgaris | 49.0 | 249.5 | 11.3 | 11.3 | 238.2 | Expected to be fully utilised by June 2024 |
| Clinical development of GT20029 for the treatment of AGA and acne vulgaris | 27.0 | 137.5 | 30.8 | 30.8 | 106.7 | Expected to be fully utilised by June 2024 |

| | Revised allocation of net proceeds % HKD (million) | Utilised net proceeds during the six months ended 30 June 2023 HKD (million) | Utilised net proceeds up to 30 June 2023 HKD (million) | Unutilised net proceeds as at 30 June 2023 HKD (million) | Expected timeline for utilizing the remaining balance of net proceeds from the top-up placing |
|---|---|--|--|--|--|
| Clinical development and preparation for the commercialisation of proxelutamide for the treatment of COVID-19 | 15.0 | 76.4 | 76.4 | 76.4 | – |
| General working capital | 9.0 | 45.8 | 45.8 | 45.8 | – |
| Total | 100.0 | 509.1 | 164.3 | 164.3 | 344.9 |

The above supplemental information does not affect other information contained in the 2022 Annual Report and the 2023 Interim Report. Save as disclosed above, all other information in the 2022 Annual Report and 2023 Interim Report remains unchanged.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong

Chairman, Executive Director and Chief Executive Officer

Hong Kong, 28 September 2023

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong, Dr. Qun Lu and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*